USNA auf dem Weg zu 500% dieses Jahr.

Somit sind die angekündigten 500% schon lange Makulatur, es sind deutlich mehr geworden.

Alles erledigt, Datenbank steht.

Bis die Nächte.

Gruss E.

ste USNA ausgegraben. Ist glaub ich nur von uns zwei Hübschen durchgesprochen worden.
Die "Mad Cows" waren ein Geschenk gratis für EDET.
Auf baldige Zweiarmigkeit. ( ENCY fast durch die 10, alter Freak )

Gruss E.

chart.bigcharts.com/bc3/quickchart/...62&mocktick=1&rand=6463"

Fans of Atkins(R) Find Non-Beef Alternatives at eDiets.com(TM)  
TUESDAY, DECEMBER 30, 2003 4:20 PM
- PR Newswire

 EDET
 6.16  +0.11  

DEERFIELD BEACH, Fla., Dec 30, 2003 /PRNewswire-FirstCall via Comtex/ -- Followers of the Atkins Nutritional Approach(R) have plenty of non-beef options to choose from at eDiets.com, a leading online diet destination for consumers seeking personalized advice, nutrition information, products and services. eDiets.com makes it possible to adhere to the low-carbohydrate philosophy espoused by the Atkins Nutritional Approach.

"When it comes to dieting, we all know how easy it is to fall off the wagon," said Susan Burke, Director of Nutrition Services at eDiets.com. "If you're concerned about eating beef right now, our flexible meal plans allow you to exclude beef, and include chicken, fish and pork, if you choose. All meals have exactly the elements every Atkins Nutritional Approach meal should have."

The long list of non-beef options available from Atkins Nutritional Approach at eDiets.com include roast chicken with baked Brie and sun-dried tomatoes, salsa fish with salad, shrimp and broccoli stir-fry, an open-face roast pork sandwich on Atkins bread, and roast chicken almond salad. Consumers have a wide range of choices with Atkins. For more information on these and other alternatives, go to www.eDiets.com.

eDiets.com has enjoyed significant success with its personalized version of the Atkins Nutritional Approach, which includes customized meal plans catering to individual needs and preferences, daily menus, shopping lists and 24/7 online support. The Atkins plan has been available at www.eDiets.com since April 2003, and has already become one of eDiets most popular options.

eDiets.com has translated Atkins' four-phase program that starts by limiting refined carbohydrates from sugar and refined flour products, and includes liberal portions of protein and healthy fats. As members progress toward their goal weight, the program adds back graduated portions of healthy carbs, including fruits and vegetables, grains, nuts and dairy.

About eDiets.com

eDiets.com is the premier online "diet destination" for consumers seeking professional advice, information, products and services that challenge overweight individuals both domestically and abroad to get in shape to live longer. Over 1.3 million consumers worldwide have become eDiets.com members since its inception in 1996.

eDiets.com offers 15 personalized programs including the Atkins Nutritional Approach(R), the Zone Diet(TM), Shape Up!(TM) inspired by Dr. Phil McGraw's Ultimate Weight Solution, the eDiets.com Alternative to Jenny Craig, and more than a dozen specialized healthy living programs for those with special needs, including Type 2 Diabetes, Heart Smart and The Vegetarian Diet.

Members choose a plan and complete a personal profile questionnaire to determine how to best custom tailor the program for their unique needs. Each meal plan is personalized for the member's food preferences and lifestyle, and custom shopping lists are provided that allow members to buy everything for the plan at the supermarket. To ensure success, members have 24/7/365 access to eDiets.com's "Support Central" through which they can garner real-time motivation and support from eDiets.com's on-staff experts and member peers. An eDiets.com nutrition program costs $5 per week, and members can change among available plans at their discretion at no additional charge; personalized fitness costs an additional $1 per week.

Dieting is a $30 billion market with established brands such as Jenny Craig(R), Weight Watchers(R) and several regional brands. Founded in 1996, eDiets.com is a public company (EDET) headquartered in Deerfield Beach, FL. that operates Web sites at www.eDiets.com and www.eFitness.com, as well as www.eDietsuk.co.uk in Ireland and the United Kingdom and www.eDiets.de in Germany.


     CORPORATE CONTACT:                      MEDIA CONTACT:
     Merilee Kern,                           Eric Goldman, Neale-May & Partners
     Manager Marketing Communications        Vice President
     954-360-9022                            212-213-5400x202
     merilee@eDiets.com                      egoldman@nealemay.com


SOURCE eDiets.com

Corporate - Merilee Kern, Manager Marketing Communications of
eDiets.com, +1-954-360-9022, merilee@eDiets.com; or Media - Eric Goldman, Vice
President of Neale-May & Partners, +1-212-213-5400, ext. 202,
egoldman@nealemay.com, for eDiets.com


www.prnewswire.com

30 % auf 3,70.

Gruss E.

Genaissance Pharmaceuticals, Inc. is a world leader in the discovery and use of
human gene variation for the development of a new generation of DNA-based
diagnostic and therapeutic products. Genaissance markets its technology,
clinical development skills and pharmacogenomic services to the pharmaceutical
industry as a complete solution for improving the development, marketing and
prescribing of drugs. Genaissance has agreements with major pharmaceutical,
diagnostic and biotechnology companies. Genaissance is headquartered in Science
Park in New Haven, Connecticut. Visit the company's website at
www.genaissance.com.

This press release contains forward-looking statements, including statements
about the expected growth and development of Genaissance's business and market
opportunities, the ability of Genaissance to apply its technologies to the
development, marketing and prescribing of drugs and to detect associations
between clinical outcomes and genetic variation. Such statements are subject to
certain factors, risks and uncertainties that may cause actual results, events
and performance to differ materially from those referred to in such statements,
including, but not limited to, the extent to which genetic markers (haplotypes)
are predictive of clinical outcomes and drug efficacy and safety, the attraction
of new business and strategic partners, the adoption of our technologies by the
pharmaceutical industry, the timing and success of clinical trials, competition
from pharmaceutical, biotechnology and diagnostics companies, the strength of
our intellectual property rights and those risks identified in our Quarterly
Report on Form 10-Q filed with the Securities and Exchange Commission on
November 14, 2003, and in other filings we make with the Securities and Exchange
Commission from time to time. The forward-looking statements contained herein
represent the judgment of Genaissance as of the date of this release.
Genaissance disclaims any obligation to update any forward-looking statement.

SOURCE Genaissance Pharmaceuticals, Inc.

Und der innere Wert steigt durch die Lark Aquisition. Lark hat mal 500 Dollar gekostet, lang ists her.

Gruss E.

chart.bigcharts.com/bc3/quickchart/...27&mocktick=1&rand=2373"

Genaissance Pharmaceuticals, Inc. to Acquire Lark Technologies, Inc. - Acquisition Complements Genaissance's Pharmacogenomic Base Business - - Significantly Increases Revenues; Adds Profitable Operation and UK Facility -  


NEW HAVEN, Conn., and HOUSTON, Dec 19, 2003 /PRNewswire-FirstCall via Comtex/
-- Genaissance Pharmaceuticals, Inc. (Nasdaq: GNSC) and Lark Technologies, Inc (OTC Bulletin Board: LRKT) today announced that they have signed a definitive
agreement whereby Genaissance will acquire Lark in an all stock transaction.
Under the terms of the agreement, Genaissance will issue approximately 6.7
million shares of its common stock to Lark's stockholders, who will receive 1.81
shares of Genaissance's common stock for each share of Lark's common stock that
they own, and will assume outstanding Lark options exercisable for an aggregate
of approximately 1.5 million shares of Genaissance common stock. The transaction
is valued at approximately $19.9 million, based on the closing price of
Genaissance's common stock of $2.99 per share on December 18, 2003.

Following the transaction, Genaissance expects to have projected pro-forma
revenues in excess of $25 million for calendar 2004, a substantially reduced
operating loss, an expanded pharmacogenomic service and technology portfolio
with facilities in the U.S. and England and additional financial resources to
advance the development of pharmacogenomic based proprietary products. Dr. Carl
Balezentis, President and Chief Executive Officer of Lark, will join Genaissance
as Senior Vice President and President, Lark Technologies.

Lark, headquartered in Houston, Texas, with European operations located near
Cambridge, England, offers Good Laboratory Practices (GLP) compliant and
research genomic services for use in pharmaceutical, diagnostic and agricultural
product research and development. For the nine months ended September 30, 2003,
Lark reported revenues of $6.8 million, net income of $1.2 million and operating
income of $1.6 million.

"The acquisition of Lark is an exciting next step in the execution of our
strategy to build a profitable base services business while developing
proprietary products based on our HAP(TM) Technology," said Kevin Rakin,
President and Chief Executive Officer of Genaissance Pharmaceuticals. "The
addition of Lark will provide us with access to a broader client base, a GLP
sequencing capability that complements our existing GLP genotyping ability, a
strong and growing European operation and an experienced team focused on
profitable revenue generation. Most importantly, as we look forward, a
profitable base services business will generate additional funds for the
development of proprietary diagnostic and pharmaceutical products. I am also
very pleased to welcome Dr. Carl Balezentis and his team to Genaissance."

The transaction has been approved unanimously by both Boards of Directors and is
subject to shareholder approval by both companies and other customary closing
conditions. The transaction is expected to close in the first half of 2004. The
dates of special stockholder meetings for shareholders of Lark and Genaissance
will be announced at a later date.

"The combined company's capabilities will provide the pharmaceutical industry a
pharmacogenomic solution spanning early stage research through clinical
development and commercialization," said Carl W. Balezentis, Ph.D., President
and Chief Executive Officer of Lark Technologies. "By becoming part of
Genaissance, we expect to grow significantly our combined business through
additional product offerings, cross selling of services and technologies and the
ability to partner on specific product development opportunities. We are
especially excited about the existing and potential programs for product
development at Genaissance and the value that our shareholders may derive by
participating in the further development and commercialization of these
pharmacogenomic product programs."

Legg Mason Wood Walker, Incorporated and EMA Partners, LLC served as financial
advisors to Genaissance in the transaction and Southwest Securities, Inc. served
as financial advisor to Lark Technologies.

About Lark Technologies